VivoSim Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
VivoSim Labs, Inc. (VIVS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2024-03-31, per its 10-K filed 2024-05-31.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2024-05-31
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-06-30 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-06-30 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-06-30 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-06-30 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $5.32.
- VivoSim Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $0.08, a 95.15% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-K · filed 2024-05-31 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $0.00 10-K · filed 2023-07-14 | |||
| 2022-12-31 | $0.00 10-Q · filed 2023-02-09 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $5.32 10-K · filed 2021-06-15 | |||
| 2020-12-31 | $5.32 10-Q · filed 2021-02-08 | |||
| 2020-09-30 | $5.32 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $0.00 10-Q · filed 2020-02-10 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $0.08 10-K · filed 2019-06-03 | |||
| 2018-12-31 | $0.08 10-Q · filed 2019-02-07 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $1.65 10-K · filed 2018-05-31 | |||
| 2017-12-31 | $1.65 10-Q · filed 2018-02-08 | |||
| 2017-09-30 | $1.65 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $2.38 10-K · filed 2017-06-07 | |||
| 2016-12-31 | $2.38 10-Q · filed 2017-02-09 | |||
| 2016-09-30 | $2.42 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $2.76 10-K · filed 2016-06-09 | |||
| 2015-12-31 | $2.76 10-Q · filed 2016-02-08 | |||
| 2015-09-30 | $2.94 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $3.01 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $1.73 10-K · filed 2016-06-09 | |||
| 2014-12-31 | $2.18 10-Q · filed 2015-02-06 | |||
| 2014-09-30 | $2.12 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $1.83 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $2.19 10-K · filed 2015-06-09 | |||
| 2013-12-31 | $2.33 10-Q · filed 2014-02-06 | |||
| 2013-09-30 | $2.73 10-Q · filed 2013-11-08 | |||
| 2012-12-31 | $0.08 10-K · filed 2014-06-10 | |||
| 2012-09-30 | $0.08 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |